ETNB•benzinga•
Hearing RBC Reiterates Buy And $35 Price Target On 89bio; Hearing Firm Says It Believes NASH Data From Akero Should Have Positive Read-Throughs To Probability Of Success Of Co.'s Pegoza Program
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 13, 2022 by benzinga